Physicochemical drug properties associated with in vivo toxicological outcomes: a review.
about
Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitorsIDAAPM: integrated database of ADMET and adverse effects of predictive modeling based on FDA approved drug dataPlate-based diversity subset screening generation 2: an improved paradigm for high-throughput screening of large compound filesNovel chiral skeletons for drug discovery: antibacterial tetramic acids.Probing the probes: fitness factors for small molecule tools.Synthesis and biological evaluation of water-soluble progesterone-conjugated probes for magnetic resonance imaging of hormone related cancersFinding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening and knowledge of transporters: where drug discovery went wrong and how to fix it.A novel drug discovery strategy: mechanistic investigation of an enantiomeric antitumor agent targeting dual p53 and NF-κB pathways.How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?On the translocation of bacteria and their lipopolysaccharides between blood and peripheral locations in chronic, inflammatory diseases: the central roles of LPS and LPS-induced cell death.FutureTox: building the road for 21st century toxicology and risk assessment practicesMetabolites: have we MIST out the importance of structure and physicochemistry?Guidelines for preclinical and early phase clinical assessment of novel radiosensitisersThe influence of the 'organizational factor' on compound quality in drug discovery.Why do metabolites circulate?Going further than Lipinski's rule in drug design.In silico ADME/T modelling for rational drug design.Amphiphilic drug interactions with model cellular membranes are influenced by lipid chain-melting temperatureComputational toxicology: Its essential role in reducing drug attrition.Refinement, Reduction, and Replacement of Animal Toxicity Tests by Computational Methods.Predicting in vivo safety characteristics using physiochemical properties and in vitro assays.Development of a Novel Quantitative Structure-Activity Relationship Model to Accurately Predict Pulmonary Absorption and Replace Routine Use of the Isolated Perfused Respiring Rat Lung Model.Discovery of Brain-Penetrant, Irreversible Kynurenine Aminotransferase II Inhibitors for Schizophrenia.Towards a more robust approach to selecting and prosecuting promising targets and compounds.Structural basis for the agonist action at free fatty acid receptor 1 (FFA1R or GPR40).An integrated suite of modeling tools that empower scientists in structure- and property-based drug design.Thermodynamic Profiling of Carbonic Anhydrase InhibitorsTarget validation using in-cell small molecule clickable imaging probesChemical motifs that redox cycle and their associated toxicity
P2860
Q27673353-DCD11467-C6C1-4BD8-ACBB-0FC75B67E645Q27902312-10A9F4C3-C09C-45A7-B404-AD363D4AD0FDQ28822337-52F30AB1-DBFD-4ECC-BDD2-49F0F7A61785Q33893201-D2E0BED6-8902-42EE-9346-E22AE75578D7Q34001269-434A4545-1501-4741-99D5-695FE65590AFQ34040411-343E9241-CBD3-4CE5-AB93-6466428EC180Q34646772-0E513061-7688-4702-98A2-B59C9230869AQ34786578-9C03756D-F57A-4BCA-9414-6441616704ECQ35036150-2A1148AF-A676-4D72-A23B-F552AF67DE18Q35765830-BE537E9C-7048-4648-A48A-520B2F462EF6Q37537481-6EADB2FE-ADE5-44CE-8477-33A6A8D565A8Q37810225-DF46494B-F017-4BB4-AFC7-47759C911B9FQ37902873-61B00F03-8CA4-4A1E-ADFF-A6D9308CC65EQ37940789-07F6C404-33DF-4605-931F-7D6886DABF77Q37960646-75E766DF-E512-4707-B0DE-58A440AF4B1BQ37999092-91381DAE-29C0-47C7-B757-3E84C096CB7BQ38578341-ED9EF7AF-6831-4432-9210-3EA0CDB53F57Q38594358-79625D81-D21C-43ED-84E1-31DBFFE3DE1AQ38937780-C86CF922-DA6C-40DF-9CF2-F9BF8C8A4797Q39067502-C0C0AD1A-5C58-4A13-9DFE-AF292236A8CFQ39481089-5D185AF2-606D-44D3-94C0-C1592E0A128BQ39612986-DFB541D7-C5E1-422C-A219-D542C0AF5449Q39736371-82863C30-80DA-428D-B811-5DEFEEB486F0Q39915228-51D98948-38E1-4B7F-ACC7-8CD679AA280BQ47606086-AC03CA26-6422-4E71-9C2D-A050394E7F7CQ54275024-7C316EC7-B15F-45E8-BCEE-754DE81D2890Q58293116-693C41BB-383F-405C-B4AA-994E8608FB93Q58293218-5115129A-C995-428E-9C61-C202E230C264Q58293268-EDA850E0-3F58-4719-B1CB-D71DC56CB767
P2860
Physicochemical drug properties associated with in vivo toxicological outcomes: a review.
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Physicochemical drug properties associated with in vivo toxicological outcomes: a review.
@ast
Physicochemical drug properties associated with in vivo toxicological outcomes: a review.
@en
type
label
Physicochemical drug properties associated with in vivo toxicological outcomes: a review.
@ast
Physicochemical drug properties associated with in vivo toxicological outcomes: a review.
@en
prefLabel
Physicochemical drug properties associated with in vivo toxicological outcomes: a review.
@ast
Physicochemical drug properties associated with in vivo toxicological outcomes: a review.
@en
P2093
P2860
P1476
Physicochemical drug properties associated with in vivo toxicological outcomes: a review.
@en
P2093
David A Price
Julian Blagg
Nigel Greene
Travis Wager
P2860
P304
P356
10.1517/17425250903042318
P407
P50
P577
2009-08-01T00:00:00Z